Related references
Note: Only part of the references are listed.Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer
Chengbin Yang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2023)
Development of anti-breast cancer PI3K inhibitors based on 7-azaindole derivatives through scaffold hopping: Design, synthesis and in vitro biological evaluation
Chengbin Yang et al.
BIOORGANIC CHEMISTRY (2021)
Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation
Chengbin Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
Bo Jiang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
PI3K inhibitors are finally coming of age (Jun, 10.1038/s41573-021-00209-1, 2021)
Bart Vanhaesebroeck et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
Ya'nan Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Musa Yilmaz et al.
BLOOD CANCER JOURNAL (2019)
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A. Burris et al.
LANCET ONCOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Christophe Massard et al.
EUROPEAN JOURNAL OF CANCER (2017)
Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors
Yan-Hua Fan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
Florent Beaufils et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor
Jinsong Han et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Michele C. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection
Genevra Pillinger et al.
ONCOTARGET (2016)
Acute Myeloid Leukemia: A Concise Review
Jennifer N. Saultz et al.
JOURNAL OF CLINICAL MEDICINE (2016)
mTOR: a pharmacologic target for autophagy regulation
Young Chul Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Applications of Fluorine in Medicinal Chemistry
Eric P. Gillis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis
J. Bertacchini et al.
LEUKEMIA (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The role of ligand efficiency metrics in drug discovery
Andrew L. Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
Pascal Furet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Christopher A. Lipinski et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
B. Markman et al.
ANNALS OF ONCOLOGY (2012)
A Force Field with Discrete Displaceable Waters and Desolvation Entropy for Hydrated Ligand Docking
Stefano Forli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
Sophie Park et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
Jonathan B. Baell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Steven D. Knight et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
Alberto M. Martelli et al.
ONCOTARGET (2010)
Functional proteomic profiling of AML predicts response and survival
Steven M. Kornblau et al.
BLOOD (2009)
Targeted therapy in acute myeloid leukaemia: current status and future directions
Camilla Stapnes et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
A new Pharmacologic action of CCI-779 involves FKBP12-Independent inhibition of mTOR kinase activity and profound repression of global protein synthesis
Boris Shor et al.
CANCER RESEARCH (2008)
Fluorine in medicinal chemistry
Sophie Purser et al.
CHEMICAL SOCIETY REVIEWS (2008)
The many roles for fluorine in medicinal chemistry
William K. Hagmann
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Jerome Tamburini et al.
BLOOD (2008)
The influence of drug-like concepts on decision-making in medicinal chemistry
Paul D. Leeson et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients
Jerome Tamburini et al.
BLOOD (2007)
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia
A. M. Martelli et al.
LEUKEMIA (2006)
PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κB, MAPkinase and p53 pathways
VL Grandage et al.
LEUKEMIA (2005)
Share Paper
